All In MedTech

FDA Clearance Tracker · P160048-S006

Eversense Continuous Glucose Monitoring System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 6, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 6, 2019

Approved

Time to decision

192 days

Received Nov 26, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P160048-S006
Device name
Eversense Continuous Glucose Monitoring System
Applicant location
Germantown, MD
Received
Nov 26, 2018
Decided
Jun 6, 2019
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P160048

Device type

Device class
Class III

Every decision under product code QHJ

FDA's approval statement

As written in FDA's record.

Approval for the Eversense CGM System. The device is indicated for continually measuring glucose levels in adults (age 18 and older) with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose measurements for diabetes treatment decisions.The system is intended to:1) Provide real-time glucose readings;2) Provide glucose trend information; and3) Provide alerts for the detection and prediction of episodes of low blood glucose (hypoglycemia) and high blood glucose (hyperglycemia).The system is a prescription device. Historical data from the system can be interpreted to aid in providing therapy adjustments. These adjustments should be based on patterns seen over time. The system is intended for single patient use.

Source documents

Other decisions for Senseonics, Incorporated

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

4 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.